IN2012DN02469A - - Google Patents

Download PDF

Info

Publication number: IN2012DN02469A
Authority: IN; India
Prior art keywords: compounds; disorders; abnormal; diseases; raf
Prior art date: 2009-08-28

Application number

Other languages

English (en)

Inventor

Shenlin Huang

Xianming Jin

Zuosheng Liu

Daniel Poon

John E Tellew

Yongqin Wan

Xing Wang

Yongping Xie

Original Assignee

Irm Llc

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-28

Filing date

2010-08-27

Publication date

2015-08-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42782253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02469(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-08-27 Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc

2015-08-21 Publication of IN2012DN02469A publication Critical patent/IN2012DN02469A/en

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
230000002159 abnormal effect Effects 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract 1
101100381978 Mus musculus Braf gene Proteins 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000002074 deregulated effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Pyridine Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IN2469DEN2012 2009-08-28 2010-08-27 IN2012DN02469A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US23807309P	2009-08-28	2009-08-28
US31303910P	2010-03-11	2010-03-11
PCT/US2010/046930 WO2011025927A1 (fr)	2009-08-28	2010-08-27	Composés et compositions en tant qu'inhibiteurs de protéine kinase

Publications (1)

Publication Number	Publication Date
IN2012DN02469A true IN2012DN02469A (fr)	2015-08-21

Family

ID=42782253

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN2469DEN2012 IN2012DN02469A (fr)	2009-08-28	2010-08-27

Country Status (49)

Country	Link
US (12)	US8501758B2 (fr)
EP (2)	EP2727918B1 (fr)
JP (2)	JP5475888B2 (fr)
KR (1)	KR101413392B1 (fr)
CN (2)	CN103896921B (fr)
AR (1)	AR077975A1 (fr)
AU (1)	AU2010286569C1 (fr)
BR (1)	BR112012004453B1 (fr)
CA (1)	CA2771775C (fr)
CL (1)	CL2012000340A1 (fr)
CO (1)	CO6612222A2 (fr)
CR (1)	CR20120102A (fr)
CU (1)	CU24110B1 (fr)
CY (3)	CY1118452T1 (fr)
DK (2)	DK2727918T3 (fr)
DO (1)	DOP2012000051A (fr)
EA (2)	EA201500175A1 (fr)
EC (2)	ECSP12011700A (fr)
ES (2)	ES2492499T3 (fr)
GE (1)	GEP20146102B (fr)
GT (1)	GT201200053A (fr)
HN (1)	HN2012000441A (fr)
HR (2)	HRP20140799T1 (fr)
HU (3)	HUE032847T2 (fr)
IL (1)	IL218084A (fr)
IN (1)	IN2012DN02469A (fr)
JO (1)	JO3002B1 (fr)
LT (3)	LT2727918T (fr)
LU (2)	LUC00101I2 (fr)
MA (1)	MA33604B1 (fr)
ME (2)	ME02684B (fr)
MX (1)	MX2012002546A (fr)
MY (1)	MY156259A (fr)
NI (1)	NI201200029A (fr)
NL (1)	NL300973I2 (fr)
NO (2)	NO2019012I1 (fr)
NZ (1)	NZ598924A (fr)
PE (1)	PE20120861A1 (fr)
PL (2)	PL2470526T3 (fr)
PT (2)	PT2727918T (fr)
RS (2)	RS55568B1 (fr)
SG (2)	SG10201405311TA (fr)
SI (2)	SI2727918T1 (fr)
SM (3)	SMT201700036T1 (fr)
TN (1)	TN2012000081A1 (fr)
UA (1)	UA112285C2 (fr)
UY (1)	UY32860A (fr)
WO (1)	WO2011025927A1 (fr)
ZA (1)	ZA201202020B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3002B1 (ar) *	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
CA2789696C (fr)	2010-02-25	2017-11-07	Dana-Farber Cancer Institute, Inc.	Mutations de braf conferant une resistance aux inhibiteurs de braf
US8907270B2 (en)	2010-06-30	2014-12-09	Schlumberger Technology Corporation	Method and apparatus for gain regulation in a gamma detector
JP6150813B2 (ja) *	2011-11-11	2017-06-21	ノバルティスアーゲー	増殖性疾患の治療方法
CA2856406C (fr)	2011-11-23	2020-06-23	Novartis Ag	Formulations pharmaceutiques
US9408885B2 (en)	2011-12-01	2016-08-09	Vib Vzw	Combinations of therapeutic agents for treating melanoma
CN103159736B (zh) *	2011-12-10	2015-05-13	通化济达医药有限公司	取代的吡唑激酶抑制剂
TW201331194A (zh) *	2011-12-23	2013-08-01	Millennium Pharm Inc	雜芳基化合物及其用途
TR201808010T4 (tr)	2012-03-28	2018-06-21	Dana Farber Cancer Inst Inc	RAF inhibitörlerine direnç veren C-RAF mutantları.
IN2015DN00099A (fr)	2012-07-18	2015-05-29	Univ Saint Louis
US8716226B2 (en)	2012-07-18	2014-05-06	Saint Louis University	3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
AR091876A1 (es) *	2012-07-26	2015-03-04	Novartis Ag	Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
IN2015DN00450A (fr) *	2012-08-07	2015-06-26	Novartis Ag
DK2884979T3 (da)	2012-08-17	2019-09-02	Hoffmann La Roche	Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
WO2014047330A1 (fr) *	2012-09-19	2014-03-27	Jean-Michel Vernier	Nouveaux inhibiteurs de raf kinase
HK1214765A1 (zh)	2012-11-08	2016-08-05	Novartis Ag	包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
US9913844B2 (en) *	2013-03-21	2018-03-13	Novartis Ag	Combination therapy
TWI634114B (zh) *	2013-05-08	2018-09-01	永恒生物科技公司	作為激酶抑制劑之呋喃酮化合物
RU2015149937A (ru) *	2013-05-30	2017-07-06	Плексксикон Инк.	Соединения для модулирования киназы и показания к их применению
EP3049442A4 (fr)	2013-09-26	2017-06-28	Costim Pharmaceuticals Inc.	Méthodes de traitement de cancers hématologiques
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112016014481B1 (pt) *	2013-12-20	2022-11-08	Biomed Valley Discoveries, Inc	Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
AU2014372166B2 (en) *	2013-12-23	2017-10-26	Novartis Ag	Pharmaceutical combinations
UA122479C2 (uk)	2014-01-24	2020-11-25	Дана-Фарбер Кенсер Інстітьют, Інк.	Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl)	2014-01-31	2019-10-31	Novartis Ag	Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
DE102015103158A1 (de)	2014-03-04	2015-09-10	Bergische Universität Wuppertal	Verbindungen für die Behandlung des Melanoms
EA201691765A1 (ru)	2014-03-14	2016-12-30	Новартис Аг	Молекулы антител против lag-3 и их применения
WO2015145388A2 (fr)	2014-03-27	2015-10-01	Novartis Ag	Procédés de traitement de cancers colorectaux avec mutations en amont de la voie wnt
WO2015175846A2 (fr) *	2014-05-16	2015-11-19	University Of Massachusetts	Traitement de la leucémie myéloïde chronique (lmc)
US20170114323A1 (en)	2014-06-19	2017-04-27	Whitehead Institute For Biomedical Research	Uses of kinase inhibitors for inducing and maintaining pluripotency
JP6636014B2 (ja) *	2014-09-12	2020-01-29	ノバルティスアーゲー	Ｒａｆキナーゼ阻害剤としての化合物および組成物
EP3191126B1 (fr)	2014-09-13	2020-05-13	Novartis AG	Thérapies combinées d'inhibiteurs d'alk
KR20170066546A (ko)	2014-10-03	2017-06-14	노파르티스 아게	조합 요법
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702401RA (en)	2014-10-14	2017-04-27	Novartis Ag	Antibody molecules to pd-l1 and uses thereof
TWI706958B (zh)	2015-03-10	2020-10-11	美商艾杜諾生物科技公司	活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
US20180340025A1 (en)	2015-07-29	2018-11-29	Novartis Ag	Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (fr)	2015-07-29	2018-06-06	Novartis AG	Traitements combinés comprenant des molécules d'anticorps qui se lient à pd-1
US20180207273A1 (en)	2015-07-29	2018-07-26	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
PT3370768T (pt)	2015-11-03	2022-04-21	Janssen Biotech Inc	Anticorpos que se ligam especificamente ao pd-1 e seus usos
CN108495651A (zh)	2015-12-17	2018-09-04	诺华股份有限公司	抗pd-1的抗体分子及其用途
HK1244806A1 (zh)	2015-12-30	2018-08-17	Saint Louis University	作為過氧乙醯硝酸整聯蛋白拮抗劑的間氮雜環氨基苯甲酸衍生物
RU2615986C1 (ru) *	2016-02-25	2017-04-12	Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм")	Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
BR112018074941A2 (pt)	2016-06-03	2019-03-12	Caponigro Giordano	combinações farmacêuticas
EP3507367A4 (fr)	2016-07-05	2020-03-25	Aduro BioTech, Inc.	Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
EP3564232B1 (fr) *	2016-12-27	2022-01-26	Riken	Composé inhibiteur de signal bmp
EP3579872A1 (fr)	2017-02-10	2019-12-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107540699A (zh) *	2017-10-16	2018-01-05	康化（上海）新药研发有限公司	一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法
CA3086765A1 (fr)	2017-12-28	2019-07-04	Tract Pharmaceuticals, Inc.	Systemes de culture de cellules souches pour cellules souches epitheliales colonnaires, et leurs utilisations
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2020011141A1 (fr) *	2018-07-12	2020-01-16	深圳市塔吉瑞生物医药有限公司	Composé diarylpyrazole, composition le comprenant et utilisation associée
WO2020124397A1 (fr) *	2018-12-19	2020-06-25	Inventisbio Shanghai Ltd.	Inhibiteurs de kinase src c-terminale
BR112021011894A2 (pt)	2018-12-21	2021-09-08	Daiichi Sankyo Company, Limited	Composição farmacêutica
JP7234418B2 (ja)	2019-05-16	2023-03-07	イーライリリーアンドカンパニー	Ｂｒａｆｖ６００ｅ大腸癌の治療に使用するためのｅｒｋ１／２阻害剤と、ｂｒａｆ阻害剤およびｅｇｆｒ阻害剤との三重組み合わせ
CN114746419B (zh)	2019-12-05	2023-10-24	国家医疗保健研究所	N-(3-(5-(嘧啶-4-基)噻唑-4-基)苯基)磺酰胺化合物及其用作braf抑制剂的用途
MX2022015703A (es)	2020-06-09	2023-01-24	Array Biopharma Inc	Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
US20230303551A1 (en)	2020-08-13	2023-09-28	Albert Einstein College Of Medicine	N-cyclyl-sulfonamides useful for inhibiting raf
WO2022074011A1 (fr)	2020-10-05	2022-04-14	Pierre Fabre Medicament	Association d'encorafénib et de binimétinib comme traitement adjuvant pour un mélanome de stade ii réséqué
EP4308935A1 (fr)	2021-03-18	2024-01-24	Novartis AG	Biomarqueurs pour le cancer et leurs méthodes d'utilisation
US12371667B2 (en)	2021-05-13	2025-07-29	Washington University	Enhanced methods for inducing and maintaining naive human pluripotent stem cells
CN117642166A (zh)	2021-06-09	2024-03-01	中外制药株式会社	用于癌症治疗的组合疗法
CN114181197B (zh) *	2022-02-16	2022-05-06	北京康立生医药技术开发有限公司	一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023230554A1 (fr)	2022-05-25	2023-11-30	Pfizer Inc.	Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf
WO2024163166A1 (fr) *	2023-01-30	2024-08-08	5Metis, Inc.	Composés contenant du bore et leurs utilisations
KR20250166103A (ko)	2023-04-06	2025-11-27	에자이 알앤드디 매니지먼트 가부시키가이샤	종양 치료용 약제학적 조성물
CN116396222A (zh) *	2023-04-10	2023-07-07	上海睿腾医药科技有限公司	一种康奈非尼中间体1-（3-氨基-1-异丙基-1h-吡唑-4-基）乙-1-酮的合成方法
WO2025003956A1 (fr)	2023-06-30	2025-01-02	Pfizer Inc.	Formulations d'encorafénib à forte charge médicamenteuse

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4104250A (en) *	1976-08-11	1978-08-01	Borg-Warner Corporation	Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
JPS5475888A (en)	1977-11-29	1979-06-18	Jiyasuko Kk	Surgical laser
EP0184384B1 (fr)	1984-12-06	1989-08-02	Pfizer Inc.	Acides dihydroquinolonecarboxyliques substitués et compositions antibactériennes les contenant
US6358932B1 (en)	1994-05-31	2002-03-19	Isis Pharmaceticals, Inc.	Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en)	1994-05-31	2002-05-21	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of raf gene expression
US6037136A (en)	1994-10-24	2000-03-14	Cold Spring Harbor Laboratory	Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
EP0952770A4 (fr)	1995-09-07	1999-12-22	Fuisz Technologies Ltd	Systeme permettant de rendre biodisponibles des agents bioalterants sensiblement non solubles
US5717100A (en)	1995-10-06	1998-02-10	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IL127210A0 (en)	1996-05-23	1999-09-22	Applied Research Systems	Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use
AR012634A1 (es)	1997-05-02	2000-11-08	Sugen Inc	Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
NZ501112A (en)	1997-05-22	2002-10-25	G	Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en)	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
US6187799B1 (en)	1997-05-23	2001-02-13	Onyx Pharmaceuticals	Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en)	1997-08-06	1997-10-08	Glaxo Group Ltd	Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en)	1997-11-07	2000-02-08	Amgen Inc.	Substituted pyridine compounds and methods of use
US6204467B1 (en)	1998-03-24	2001-03-20	Ford Global Technologies, Inc.	Method and apparatus for resistive welding
US7351834B1 (en)	1999-01-13	2008-04-01	Bayer Pharmaceuticals Corporation	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6316435B2 (en)	1999-02-24	2001-11-13	Supergen, Inc.	Combination therapy for lymphoproliferative diseases
JP5159012B2 (ja)	1999-12-23	2013-03-06	メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド	不良溶解性の薬物に対する改良された医薬組成物
US6756410B2 (en)	2000-08-30	2004-06-29	Kamal D. Mehta	Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2
PE20020354A1 (es)	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
NZ552335A (en)	2001-10-25	2008-11-28	Novartis Ag	Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent
JP4399265B2 (ja)	2001-12-21	2010-01-13	ヴァーナリス（ケンブリッジ）リミテッド	３，４−ジアリールピラゾール、および癌の治療におけるそれらの使用
SG2013013339A (en)	2002-03-13	2014-12-30	Array Biopharma Inc	N3 alkylated benzimidazole derivatives as mek inhibitors
EA200600495A1 (ru)	2003-09-23	2006-10-27	Новартис Аг	Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
AU2004289539C1 (en)	2003-11-14	2012-06-07	Lorus Therapeutics Inc.	Aryl imidazoles and their use as anti-cancer agents
CA2551948A1 (fr)	2004-01-09	2005-07-28	Novartis Ag	Derives de phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine utilises comme inhibiteurs du recepteur igf-1r
MXPA06014247A (es)	2004-06-10	2007-03-12	Irm Llc	Compuestos y composiciones como inhibidores de la proteina quinasa.
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
WO2006102079A1 (fr)	2005-03-17	2006-09-28	Novartis Ag	N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2, 4, 4b-triazafluoren-9-yle)-phenyl] benzamides utilises en tant qu'inhibiteurs de tyrosine/threonine kinase, en particulier la b-raf kinase
US20070099856A1 (en)	2005-05-13	2007-05-03	Gumerlock Paul H	Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
WO2007021966A1 (fr)	2005-08-12	2007-02-22	Synta Pharmaceuticals Corp.	Composes pyrazoles modulant l'activite de la proteine hsp90
RU2442574C2 (ru)	2005-08-22	2012-02-20	Новартис Аг	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ pН-ЗАВИСИМОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, МОДИФИКАТОР pН И ЗАМЕДЛЯЮЩИЙ АГЕНТ
EP1917258A2 (fr)	2005-08-26	2008-05-07	SmithKline Beecham Corporation	Inhibiteurs de pyrimidinyl-pyrazole d'aurora kinases
PE20070335A1 (es)	2005-08-30	2007-04-21	Novartis Ag	Benzimidazoles sustituidos y metodos para su preparacion
CA2643066A1 (fr) *	2006-03-16	2007-09-20	Pfizer Products Inc.	Pyrazoles
CN101415411A (zh)	2006-04-05	2009-04-22	诺瓦提斯公司	用于治疗癌症的治疗剂组合
WO2007123892A2 (fr) *	2006-04-17	2007-11-01	Arqule Inc.	Inhibiteurs raf et leurs utilisations
SG174772A1 (en)	2006-09-11	2011-10-28	Curis Inc	Multi-functional small molecules as anti-proliferative agents
CA2663599A1 (fr)	2006-09-18	2008-03-27	Boehringer Ingelheim International Gmbh	Procede de traitement du cancer presentant des mutations egfr
AU2007305016B2 (en)	2006-10-02	2011-11-03	Novartis Ag	Compounds and compositions as protein kinase inhibitors
WO2008045627A2 (fr) *	2006-10-06	2008-04-17	Irm Llc	Inhibiteurs de la protéine kinase et procédés pour utiliser ceux-ci
CA2677651A1 (fr)	2007-02-15	2008-08-21	Novartis Ag	Combinaisons d'agents therapeutiques pour le traitement du cancer
US20090022789A1 (en)	2007-07-18	2009-01-22	Supernus Pharmaceuticals, Inc.	Enhanced formulations of lamotrigine
BRPI0815042A2 (pt) *	2007-08-01	2015-02-10	Pfizer	Compostos de pirazol
BRPI0818340A2 (pt)	2007-10-19	2015-04-22	Abbott Gmbh & Co Kg	Produto de dispersão sólida de fármacos baseados em n-aril uréia
CA2704436C (fr) *	2007-11-14	2016-01-05	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Derives imidazo[1,2-a]pyridine et leur utilisation comme modulateurs allosteriques positifs des recepteurs mglur2
WO2009115572A2 (fr) *	2008-03-21	2009-09-24	Novartis Ag	Nouveaux composés hétérocycliques et leurs utilisations
UA103319C2 (en) *	2008-05-06	2013-10-10	Глаксосмитклайн Ллк	Thiazole- and oxazole-benzene sulfonamide compounds
EP2324008B1 (fr)	2008-07-24	2012-05-09	Nerviano Medical Sciences S.R.L.	3,4-diarylpyrazoles utilisés comme inhibiteurs de protéine kinase
KR20110038159A (ko)	2008-07-28	2011-04-13	길리애드 사이언시즈, 인코포레이티드	사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
EP2350052B1 (fr)	2008-09-29	2014-08-13	Boehringer Ingelheim International GmbH	Composés antiprolifératifs
EP2346495B2 (fr)	2008-10-07	2023-05-24	Kudos Pharmaceuticals Limited	Formulation pharmaceutique 514
WO2010056662A1 (fr) *	2008-11-11	2010-05-20	University Of Washington	Signalisation de wnt-bêta-caténine dans le mélanome
ES2422263T3 (es)	2008-12-19	2013-09-10	Nerviano Medical Sciences Srl	Pirazoles bicíclicos como inhibidores de la proteinquinasa
AR075180A1 (es)	2009-01-29	2011-03-16	Novartis Ag	Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru)	2009-02-12	2010-10-27	Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН	КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (fr)	2009-03-04	2010-09-10	Novartis Ag	Dérivés d'imidazole disubstitués en tant que modulateurs de la protéine kinase raf
TWI532484B (zh)	2009-06-08	2016-05-11	艾伯維有限公司	包含凋亡促進劑之固態分散劑
EP3045457B1 (fr) *	2009-06-15	2018-05-09	Nerviano Medical Sciences S.r.l.	Dérivés de pyrimidinylpyrrolopyridinone substitués, leur procédé de préparation et leur utilisation en tant qu'inhibiteurs de kinase
KR101256018B1 (ko) *	2009-08-20	2013-04-18	한국과학기술연구원	단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
JO3002B1 (ar)	2009-08-28	2016-09-05	Irm Llc	مركبات و تركيبات كمثبطات كيناز بروتين
US8242260B2 (en) *	2009-08-28	2012-08-14	Novartis Ag	Compounds and compositions as protein kinase inhibitors
AU2011209234B2 (en)	2010-01-27	2015-05-07	Nerviano Medical Sciences S.R.L.	Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
SG10201502484SA (en)	2010-03-30	2015-05-28	Verseon Corp	Multisubstituted aromatic compounds as inhibitors of thrombin
JP5938038B2 (ja)	2010-08-03	2016-06-22	ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ	ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
HUE032100T2 (en)	2011-03-21	2017-08-28	Valcuria Ab	A pharmaceutical composition comprising an HDAC inhibitor and a steroid and its use
CN103608012A (zh)	2011-06-14	2014-02-26	诺华股份有限公司	在癌症如骨髓增殖性肿瘤治疗中的帕比司他与鲁索利替尼的组合
JP6150813B2 (ja)	2011-11-11	2017-06-21	ノバルティスアーゲー	増殖性疾患の治療方法
CA2856406C (fr)	2011-11-23	2020-06-23	Novartis Ag	Formulations pharmaceutiques
HK1214765A1 (zh)	2012-11-08	2016-08-05	Novartis Ag	包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
US10576680B2 (en)	2015-11-19	2020-03-03	The Boeing Company	Modular thermoforming system

2010
- 2010-08-26 JO JOP/2010/0297A patent/JO3002B1/ar active
- 2010-08-26 AR ARP100103123A patent/AR077975A1/es active IP Right Grant
- 2010-08-27 DK DK14152945.3T patent/DK2727918T3/da active
- 2010-08-27 ME MEP-2017-6A patent/ME02684B/fr unknown
- 2010-08-27 US US12/870,130 patent/US8501758B2/en not_active Ceased
- 2010-08-27 PT PT141529453T patent/PT2727918T/pt unknown
- 2010-08-27 SG SG10201405311TA patent/SG10201405311TA/en unknown
- 2010-08-27 ME MEP-2014-94A patent/ME01860B/me unknown
- 2010-08-27 RS RS20170017A patent/RS55568B1/sr unknown
- 2010-08-27 PE PE2012000268A patent/PE20120861A1/es active IP Right Grant
- 2010-08-27 DK DK10748211.9T patent/DK2470526T3/da active
- 2010-08-27 CN CN201410040923.XA patent/CN103896921B/zh active Active
- 2010-08-27 SI SI201031371A patent/SI2727918T1/sl unknown
- 2010-08-27 SI SI201030711T patent/SI2470526T1/sl unknown
- 2010-08-27 KR KR1020127007860A patent/KR101413392B1/ko active Active
- 2010-08-27 UA UAA201203042A patent/UA112285C2/uk unknown
- 2010-08-27 UY UY0001032860A patent/UY32860A/es active IP Right Grant
- 2010-08-27 SM SM20170036T patent/SMT201700036T1/it unknown
- 2010-08-27 MX MX2012002546A patent/MX2012002546A/es active IP Right Grant
- 2010-08-27 SG SG2012009304A patent/SG178351A1/en unknown
- 2010-08-27 EA EA201500175A patent/EA201500175A1/ru unknown
- 2010-08-27 HR HRP20140799AT patent/HRP20140799T1/hr unknown
- 2010-08-27 PL PL10748211T patent/PL2470526T3/pl unknown
- 2010-08-27 WO PCT/US2010/046930 patent/WO2011025927A1/fr not_active Ceased
- 2010-08-27 MY MYPI2012000611A patent/MY156259A/en unknown
- 2010-08-27 AU AU2010286569A patent/AU2010286569C1/en active Active
- 2010-08-27 ES ES10748211.9T patent/ES2492499T3/es active Active
- 2010-08-27 CN CN201080038197.8A patent/CN102725283B/zh active Active
- 2010-08-27 PL PL14152945T patent/PL2727918T3/pl unknown
- 2010-08-27 EP EP14152945.3A patent/EP2727918B1/fr active Active
- 2010-08-27 BR BR112012004453-2A patent/BR112012004453B1/pt active IP Right Grant
- 2010-08-27 HU HUE14152945A patent/HUE032847T2/hu unknown
- 2010-08-27 NZ NZ598924A patent/NZ598924A/xx unknown
- 2010-08-27 PT PT107482119T patent/PT2470526E/pt unknown
- 2010-08-27 EP EP10748211.9A patent/EP2470526B1/fr active Active
- 2010-08-27 JP JP2012527014A patent/JP5475888B2/ja active Active
- 2010-08-27 RS RS20140430A patent/RS53489B1/sr unknown
- 2010-08-27 CA CA2771775A patent/CA2771775C/fr active Active
- 2010-08-27 IN IN2469DEN2012 patent/IN2012DN02469A/en unknown
- 2010-08-27 ES ES14152945.3T patent/ES2610825T3/es active Active
- 2010-08-27 LT LTEP14152945.3T patent/LT2727918T/lt unknown
- 2010-08-27 EA EA201200373A patent/EA025222B1/ru not_active IP Right Cessation
- 2010-08-27 CU CU2012000034A patent/CU24110B1/es active IP Right Grant
- 2010-08-27 GE GEAP201012645A patent/GEP20146102B/en unknown
2012
- 2012-02-09 CL CL2012000340A patent/CL2012000340A1/es unknown
- 2012-02-13 IL IL218084A patent/IL218084A/en active IP Right Grant
- 2012-02-17 TN TNP2012000081A patent/TN2012000081A1/en unknown
- 2012-02-24 NI NI201200029A patent/NI201200029A/es unknown
- 2012-02-24 CO CO12032570A patent/CO6612222A2/es active IP Right Grant
- 2012-02-24 DO DO2012000051A patent/DOP2012000051A/es unknown
- 2012-02-27 HN HN2012000441A patent/HN2012000441A/es unknown
- 2012-02-27 GT GT201200053A patent/GT201200053A/es unknown
- 2012-02-28 EC ECSP12011700 patent/ECSP12011700A/es unknown
- 2012-02-28 CR CR20120102A patent/CR20120102A/es unknown
- 2012-03-19 ZA ZA2012/02020A patent/ZA201202020B/en unknown
- 2012-03-23 MA MA34716A patent/MA33604B1/fr unknown
2013
- 2013-06-28 US US13/931,111 patent/US9314464B2/en active Active
2014
- 2014-02-06 JP JP2014021339A patent/JP6045519B2/ja active Active
- 2014-09-12 SM SM201400133T patent/SMT201400133B/xx unknown
2016
- 2016-01-13 US US14/994,827 patent/US9593100B2/en active Active
- 2016-01-13 US US14/994,710 patent/US9593099B2/en active Active
- 2016-03-15 US US15/070,905 patent/US10005761B2/en active Active
- 2016-06-10 US US15/179,644 patent/US9850230B2/en active Active
- 2016-06-10 US US15/179,385 patent/US9850229B2/en active Active
2017
- 2017-01-03 HR HRP20170005TT patent/HRP20170005T1/hr unknown
- 2017-01-10 CY CY20171100028T patent/CY1118452T1/el unknown
- 2017-01-19 SM SM201700036T patent/SMT201700036B/it unknown
- 2017-11-20 US US15/818,264 patent/US10568884B2/en active Active
- 2017-11-20 US US15/818,082 patent/US10576080B2/en active Active
2019
- 2019-02-12 LU LU00101C patent/LUC00101I2/fr unknown
- 2019-02-12 LU LU00102C patent/LUC00102I2/fr unknown
- 2019-03-01 HU HUS1900012C patent/HUS1900012I1/hu unknown
- 2019-03-01 HU HUS1900013C patent/HUS1900013I1/hu unknown
- 2019-03-05 NO NO2019012C patent/NO2019012I1/no unknown
- 2019-03-05 NO NO2019011C patent/NO2019011I1/no unknown
- 2019-03-07 LT LTPA2019005C patent/LTC2470526I2/lt unknown
- 2019-03-07 LT LTPA2019006C patent/LTPA2019006I1/lt unknown
- 2019-03-15 NL NL300973C patent/NL300973I2/nl unknown
- 2019-03-18 CY CY2019013C patent/CY2019013I1/el unknown
- 2019-03-18 CY CY2019014C patent/CY2019014I1/el unknown
2020
- 2020-01-14 US US16/741,937 patent/US20200323852A1/en not_active Abandoned
2021
- 2021-07-15 US US17/376,199 patent/USRE49556E1/en active Active
2022
- 2022-04-20 US US17/724,589 patent/US20230116233A1/en not_active Abandoned
2023
- 2023-01-27 EC ECSENADI20234573A patent/ECSP23004573A/es unknown

Also Published As

Publication number	Publication date
AU2010286569C1 (en)	2019-11-28
GT201200053A (es)	2014-03-27
RS53489B1 (sr)	2015-02-27
IL218084A0 (en)	2012-04-30
LTPA2019005I1 (lt)	2019-03-25
ES2492499T3 (es)	2014-09-09
EP2470526B1 (fr)	2014-05-28
UA112285C2 (uk)	2016-08-25
CL2012000340A1 (es)	2012-08-17
LUC00102I2 (fr)	2024-05-21
PT2470526E (pt)	2014-09-01
SMT201700036B (it)	2017-03-08
EA025222B1 (ru)	2016-12-30
BR112012004453B1 (pt)	2022-04-26
EA201200373A1 (ru)	2012-09-28
PT2727918T (pt)	2017-01-20
CU20120034A7 (es)	2012-06-21
BR112012004453A2 (pt)	2021-03-09
US20180297985A1 (en)	2018-10-18
US10576080B2 (en)	2020-03-03
US8501758B2 (en)	2013-08-06
CY2019013I2 (el)	2019-11-27
NL300973I2 (nl)	2022-05-05
LTC2470526I2 (lt)	2020-04-27
LT2727918T (lt)	2017-01-25
US20160280687A1 (en)	2016-09-29
CR20120102A (es)	2012-05-02
EP2470526A1 (fr)	2012-07-04
JP6045519B2 (ja)	2016-12-14
UY32860A (es)	2011-03-31
SI2470526T1 (sl)	2014-09-30
US20230116233A1 (en)	2023-04-13
AR077975A1 (es)	2011-10-05
CN103896921A (zh)	2014-07-02
ME01860B (me)	2014-12-20
DOP2012000051A (es)	2012-05-31
ECSP23004573A (es)	2023-04-28
EA201500175A1 (ru)	2015-05-29
SG178351A1 (en)	2012-03-29
EP2727918A1 (fr)	2014-05-07
US20160122324A1 (en)	2016-05-05
ZA201202020B (en)	2012-12-27
CY1118452T1 (el)	2017-07-12
JP2014098022A (ja)	2014-05-29
US10005761B2 (en)	2018-06-26
PE20120861A1 (es)	2012-07-14
NI201200029A (es)	2012-05-29
SMT201400133B (it)	2014-11-10
GEP20146102B (en)	2014-05-27
JO3002B1 (ar)	2016-09-05
US20160120866A1 (en)	2016-05-05
US9314464B2 (en)	2016-04-19
CO6612222A2 (es)	2013-02-01
IL218084A (en)	2016-11-30
AU2010286569A1 (en)	2012-04-12
CU24110B1 (es)	2015-07-30
US9850229B2 (en)	2017-12-26
BR112012004453A8 (pt)	2021-06-08
US20160263113A1 (en)	2016-09-15
US9593100B2 (en)	2017-03-14
CA2771775A1 (fr)	2011-03-03
CN103896921B (zh)	2016-02-24
SI2727918T1 (sl)	2017-02-28
HK1167390A1 (en)	2012-11-30
ES2610825T3 (es)	2017-05-03
KR101413392B1 (ko)	2014-06-27
HRP20170005T1 (hr)	2017-03-10
PL2727918T3 (pl)	2017-06-30
US20110306625A1 (en)	2011-12-15
US9850230B2 (en)	2017-12-26
TN2012000081A1 (en)	2013-09-19
SG10201405311TA (en)	2014-09-26
HUS1900012I1 (hu)	2019-04-29
US9593099B2 (en)	2017-03-14
NO2019012I1 (no)	2019-03-05
US20130296318A1 (en)	2013-11-07
JP2013503186A (ja)	2013-01-31
CY2019014I2 (el)	2019-11-27
LUC00101I2 (fr)	2020-01-23
ME02684B (fr)	2017-06-20
SMT201700036T1 (it)	2017-03-08
EP2727918B1 (fr)	2016-10-12
MA33604B1 (fr)	2012-09-01
NZ598924A (en)	2013-07-26
DK2470526T3 (da)	2014-08-25
US10568884B2 (en)	2020-02-25
MY156259A (en)	2016-01-29
PL2470526T3 (pl)	2014-10-31
CA2771775C (fr)	2015-01-20
LUC00101I1 (fr)	2019-02-13
NL300973I1 (fr)	2019-03-27
JP5475888B2 (ja)	2014-04-16
LTPA2019006I1 (lt)	2019-03-25
ECSP12011700A (es)	2012-03-30
US20200323852A1 (en)	2020-10-15
CN102725283A (zh)	2012-10-10
WO2011025927A1 (fr)	2011-03-03
KR20120062839A (ko)	2012-06-14
NO2019011I1 (no)	2019-03-05
USRE49556E1 (en)	2023-06-20
DK2727918T3 (da)	2017-01-23
CN102725283B (zh)	2014-02-26
MX2012002546A (es)	2012-04-11
HN2012000441A (es)	2015-01-05
HUE032847T2 (hu)	2017-11-28
HRP20140799T1 (hr)	2014-11-07
HUS1900013I1 (hu)	2019-04-29
US20180297986A1 (en)	2018-10-18
CY2019013I1 (el)	2019-11-27
US20160280686A1 (en)	2016-09-29
CY2019014I1 (el)	2019-11-27
AU2010286569B2 (en)	2013-10-10
RS55568B1 (sr)	2017-05-31

Publication	Publication Date	Title
TN2012000081A1 (en)	2013-09-19	Compounds and compositions as protein kinase inhibitors
PH12020550450A1 (en)	2021-06-07	Certain chemical entities, compositions and methods
MX2009011951A (es)	2009-12-11	Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009007944A (es)	2009-08-07	Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
TN2010000122A1 (en)	2011-09-26	Compounds and compositions as modulators of gpr119 activity
TN2013000348A1 (en)	2015-01-20	Compounds and compositions as trk inhibitors
PL2134704T3 (pl)	2011-03-31	Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
IN2012DN02471A (fr)	2015-08-21
MX2009011952A (es)	2009-12-11	Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
WO2011014795A3 (fr)	2011-06-03	Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
MX2009011950A (es)	2009-12-11	Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2014002486A (es)	2014-12-08	Compuestos y composiciones como inhibidores de cinasa pdgfr.
IN2012DN01961A (fr)	2015-08-21
MX2010009207A (es)	2011-03-03	Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
UY33597A (es)	2012-04-30	Compuestos y composiciones como inhibidores de la trk
MY165728A (en)	2018-04-20	Selective glycosidase inhibitors and uses thereof
MX339937B (es)	2016-06-17	Compuestos y composiciones como inhibidores de la quinasa c-kit.
PH12014500351B1 (en)	2019-04-03	COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS
TW200637547A (en)	2006-11-01	Compounds and compositions as protein kinase inhibitors
MX2009004716A (es)	2009-07-17	Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
EA200901032A1 (ru)	2010-02-26	Соединения и композиции в качестве модуляторов активности gpr119
MY172151A (en)	2019-11-14	Certain chemical entities, compositions and methods
MX2009006170A (es)	2009-06-19	Compuestos y composiciones como inhibidores de cinasa.
DE602006016449D1 (fr)	2010-10-07
WO2011014520A3 (fr)	2011-06-23	Composés et compositions pouvant servir de modulateurs de l'activité du gpr119